American Century Companies Inc. Has $3.79 Million Stake in Dynavax Technologies Corporation $DVAX

Key Points

• American Century Companies Inc. increased its stake in Dynavax Technologies Corporation by 11.5%, now owning approximately 0.24% of the company worth $3.79 million.
• In recent research reports, analysts have issued a consensus rating of "Moderate Buy" for Dynavax, with price targets ranging from $24.33 to $32.00.
• Director Scott Dunseth Myers purchased 3,800 shares of Dynavax at an average price of $10.82, increasing his holdings by 12.18% to a total of 35,004 shares.

American Century Companies Inc. lifted its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 11.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 291,883 shares of the biopharmaceutical company's stock after purchasing an additional 30,081 shares during the quarter. American Century Companies Inc. owned approximately 0.24% of Dynavax Technologies worth $3,786,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. DekaBank Deutsche Girozentrale acquired a new position in Dynavax Technologies in the 1st quarter valued at $30,000. Caitong International Asset Management Co. Ltd grew its stake in Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,304 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Dynavax Technologies in the 4th quarter valued at $35,000. GAMMA Investing LLC grew its stake in Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after buying an additional 3,627 shares during the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in Dynavax Technologies in the 1st quarter valued at $131,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of the stock in a transaction dated Friday, August 22nd. The stock was bought at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director directly owned 35,004 shares in the company, valued at $378,743.28. This represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 2.98% of the stock is currently owned by corporate insiders.

Dynavax Technologies Price Performance

DVAX stock traded down $0.15 during trading on Monday, hitting $10.12. 1,164,789 shares of the stock traded hands, compared to its average volume of 1,873,077. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -22.00 and a beta of 1.24. The company has a 50 day simple moving average of $10.62 and a 200 day simple moving average of $11.28. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.02. The firm had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Equities analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. JMP Securities restated a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.